As alternatively released system enterprises would apply, in order to register the alternatively released reward system, only if they believed that they would form larger profits by 84 Aidan Hollis the alternatively released reward system than in the regular patent system. This means that the incentives of the enterprises would be, to itself of research for taking up more highly than in the absence of the alternatively released reward system. However rewards are also not exaggerated, again by the associated draft of the system. There is an automatic adjustment mechanism in that, if the rewards become comparative too, which in the patent system is present, enterprises into the alternatively released reward system exaggerated are attractive, until the rewards per product are reduced on a level, which is comparable with the patent system. So by structure, are rewards comparably also, which can be achieved by the patent system for drugs of the comparable therapeutic effectiveness. The enterprises, which would decide inside to the system, would be with the drugs, which have high therapeutic value however fall of prices value (supposed because of the low purchasing power of the consumers). Would such rewards be sufficient to suggest research in neglected disease drugs? The patent system led too little research in drugs, which were sold mainly to poor people. The key to the alternatively released reward system is that rewards for therapeutic use are payable, rather as on the basis of commercial profitability. The alternatively released reward system essentially forms profitability of a drug-innovativedependent on therapeutic effect for those drugs, which decide inside to the system, rather as on ability to the wages of the consumers. Thus suggest alternatively released reward systemcould research in drugs, which offered the potential for credit of the very large health effects. There is that two potential problemswith the alternatively released reward system. First its system is based on direct measures and estimations of the health effects of the new drugs. Such measures are incomplete: there are numerously, incompatibly, the method teachings, which furnish different answers; the information to catch up is expensive; and it knew fraud, Lobbyismus and other Esso one gives influences. Direct measure is the best, which one can nevertheless do. There are really only three possible ways: to determine (the commercial market by the patent system, in order the rewards use 1) to the pioneer, (2) low rewards to the pioneers on therapeutic use, and (3) do not disturb to measure at all. Choice (1) is the patent system, but this works badly for neglected diseases. Advanced obligations to take delivery use choice (2) in a halfhearted kind, since I describe below. Systemof uses the transferable rights at the mental property, down descriptive, choice (3). The key question is in the absence of the meaningful measure of the health effects, is necessary it to create rewards only on commercial success and that is not with an order in agreement to improve the health arms. There of acres two potential problemswith the optionally Reward system. Roofridge, its system of relies on direct measurements and of estimates OF health impacts OF new drugs. Look for measurements acres imperfect: there acres numerous, incompatible, methodologies yielding different answers; obtaining the information is expensive; and there could fuel element fraud, lobbying, and more other look for influences. Nevertheless, direct measurement is the best that one CAN DO. There of acres really only three possible routes: (1) use the commercial market through the patent system ton determine the rewards ton the innovator, (2) base rewards tons innovators on therapeutic benefits, and (3) DO emergency measuring RK all. Option (1) is the patent system, but this functions poorly for neglected diseases. Advanced Purchase Commitments use option (2) in A help hearted way, as I describe below. A systemof Transferable Intellectual Property Rights, described below, uses option (3). The key issue is that into the absence OF meaningful measurement OF health impacts, it is necessary tons of base rewards only on commercial success, and that is emergency consistent with A mission ton improve the health OF the poor.